British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

To promote the primary prevention of hypertension and cardiovascular disease by changes in the diet and lifestyle of the whole population To increase the detection and treatment of undiagnosed hypertension by routine screening and increase awareness of hypertension among the public To ensure that pa...

Full description

Saved in:
Bibliographic Details
Published inBMJ Vol. 328; no. 7440; pp. 634 - 640
Main Authors Williams, Bryan, Poulter, Neil R, Brown, Morris J, Davis, Mark, McInnes, Gordon T, Potter, John F, Sever, Peter S, Thom, Simon McG
Format Journal Article
LanguageEnglish
Published London British Medical Journal Publishing Group 13.03.2004
BMJ Publishing Group
British Medical Association
BMJ Publishing Group LTD
BMJ Publishing Group Ltd
EditionInternational edition
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To promote the primary prevention of hypertension and cardiovascular disease by changes in the diet and lifestyle of the whole population To increase the detection and treatment of undiagnosed hypertension by routine screening and increase awareness of hypertension among the public To ensure that patients taking antihypertensive drugs are controlled to optimal blood pressure levels To reduce the risk of cardiovascular disease of treated hypertensive patients by non-pharmacological measures, and by appropriate use of statin and aspirin treatment To increase the identification and treatment of patients with mild hypertension who are at high risk of cardiovascular disease-for example, elderly patients, patients with ischaemic heart disease, people with diabetes, people with target organ damage, or people with multiple risk factors To promote continued adherence to drug treatment, by optimising the choice and use of drugs, minimising side effects, and increasing information and choice for patients. Blood pressure measurement by standard mercury sphygmomanometer or semiautomated device Use a properly maintained, calibrated, and validated device Measure sitting blood pressure routinely: standing blood pressure should be recorded at least at the initial estimation in elderly or diabetic patients Remove tight clothing, support arm at heart level, ensure arm relaxed and avoid talking during the measurement procedure Use cuff of appropriate size (see box 3 in the full guidelines, 3 http://www.bhsoc.org/ ) Lower mercury column slowly (2 mm per second) Read blood pressure to the nearest 2 mm Hg Measure diastolic blood pressure as disappearance of sounds (phase V) Take the mean of at least two readings, more recordings are needed if marked differences between initial measurements are found Do not treat on the basis of an isolated reading For full details of methods see http://www.bhsoc.org/ and reference 8 Absolute risk of cardiovascular disease estimation The treatment of hypertension and the primary prevention of cardiovascular disease should be informed by assessment of total risk of cardiovascular disease.\n The minimum acceptable level of control (audit standard) recommended is < 150/ < 90 mm Hg In people with diabetes mellitus, initiate antihypertensive drug treatment if systolic blood pressure is sustained â[per thousand]¥ 140 mm Hg or diastolic blood pressure is sustained â[per thousand]¥ 90 mm Hg In hypertensive people with diabetes, chronic renal disease, or established cardiovascular disease optimal blood pressure goals are systolic blood pressure < 130 mm Hg and diastolic blood pressure < 80 mm Hg.
Bibliography:Correspondence to: B Williams
istex:57C16254C98AFCA69594FE880993D3A7ACA5FDFA
local:bmj;328/7440/634
href:bmj-328-634.pdf
PMID:15016698
ark:/67375/NVC-6Q1WSHJP-M
ArticleID:bmj.328.7440.634
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-1
ObjectType-Feature-3
content type line 23
Correspondence to: B Williams bw17@le.ac.uk
Competing interests: All authors have received honorariums from a number of pharmaceutical companies for lectures and consultancy, and research grant support for clinical trials from the pharmaceutical industry.
Categories of strength used in statements are on bmj.com
BW is chairman of the guideline working party; NRP, MJB, MD, GTM, JFP, and PSS are members of the guideline working party; SMcGT is a member of the British Hypertension Society. The British Hypertension Society gratefully acknowledges the work done by the representatives of the many stakeholder organisations who reviewed the full guideline (appendix 1) and whose comments greatly improved the final version. We also acknowledge the outstanding administrative assistance provided by Emma Fluck at the British Hypertension Society's information service.
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.328.7440.634